{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"11.6","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"The MRD\\[-\\]CR rate was defined as the percentage of participants who reached MRD\\[-\\]CR at the 12 month landmark (8- to 13-month window). MRD\\[-\\]CR was defined as the achievement of CR (including sCR or better) per IMWG-URC by IRC assessment and MRD\\[-\\] status at a sensitivity of 10\\^-5 using next-generation sequencing based method in the bone marrow. The 90% CIs were estimated using the Clopper-Pearson method (1994).","dispersionType":"90% Confidence Interval","groups":[{"description":"Carfilzomib was administered intravenously on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression or end of study. A dose of 20 mg/m\\^2 was administered on day 1 of cycle 1; all subsequent doses were 56 mg/m\\^2. From cycle 13, the frequency of carfilzomib administration was reduced to days 1 and 15 (± 2 days) per cycle until progression or end of study.\n\nDexamethasone was administered orally or intravenously at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle during cycles 1 to 12, and at a dose of 20 mg on days 1 and 15 from cycle 13 until progression or end of study.\n\nPomalidomide 4 mg was administered orally on days 1 to 21 of each cycle until progression or end of study.","id":"OG000","title":"Carfilzomib With Pomalidomide and Dexamethasone (KPd)"}],"paramType":"NUMBER","populationDescription":"The safety analysis set included all participants who received at least 1 dose of carfilzomib. The analysis was pre-specified until PA DCO only.","reportingStatus":"POSTED","timeFrame":"Day 1 cycle 1 to month 12 (8 to 13 month window)","title":"Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}